Evidence map›Paper›PMID 42859341›Full record

ArticleInternational journal of hematology2026

Cardiovascular events in aging Japanese people with hemophilia: a 3-year interim analysis of the ADVANCE Japan cohort.

Yushi Chikasawa, Takeshi Kanematsu, Akihiro Sawada, Naoya Yamasaki, Hideyuki Takedani, Masanori Nojima, Yukio Hiroi, Teruhisa Fujii, Nobuaki Suzuki, Tadashi Matsushita and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yushi ChikasawaDepartment of Laboratory Medicine, Tokyo Medical University, Tokyo, Japan.
Takeshi KanematsuDepartment of Clinical Laboratory, Nagoya University Hospital, Aichi, Japan.
Akihiro SawadaDepartment of Hematology, Hyogo Medical University, Hyogo, Japan.
Naoya YamasakiDivision of Transfusion Medicine, Hiroshima University Hospital, Hiroshima, Japan.
Hideyuki TakedaniDepartment of Physiotherapy, National Hospital Organization Tsuruga Medical Center, Fukui, Japan.
Masanori NojimaCenter for Translational Research, The Institute of Medical Science Hospital, The University of Tokyo, Tokyo, Japan.
Yukio HiroiDepartment of Cardiology, National Center for Global Health and Medicine, Japan Institute for Health Security, Tokyo, Japan.
Teruhisa FujiiDivision of Transfusion Medicine, Hiroshima University Hospital, Hiroshima, Japan.
Nobuaki SuzukiDepartment of Transfusion Medicine, Nagoya University Hospital, Aichi, Japan.
Tadashi MatsushitaDepartment of Transfusion Medicine, Nagoya University Hospital, Aichi, Japan.
Satoshi HigasaDepartment of Hematology, Hyogo Medical University, Hyogo, Japan.
Kagehiro AmanoDepartment of Laboratory Medicine, Tokyo Medical University, Tokyo, Japan.
Azusa NagaoDepartment of Hematology and Oncology, Kansai Medical University Hospital, 2-5-1 Shin-machi, Hirakata, Osaka, 573-1010, Japan. azusanagaooo@gmail.com.ORCID http://orcid.org/0000-0002-1126-1498

Funding

Bayer Yakuhin IMPACT 20743
6 · The paper itself

Abstract

As life expectancy increases in people with hemophilia (PWH), cardiovascular disease (CVD) has emerged as an important comorbidity. However, prospective data on CVD occurrence and its clinical management remain limited. We performed a prespecified 3-year interim analysis of ADVANCE Japan, an ongoing 10-year multicenter prospective cohort study of PWH aged ≥ 40 years, to describe CVD occurrence, clinical management, bleeding outcomes, and associated changes in hemostatic treatment. We also explored factors associated with CVD occurrence using Cox proportional hazards models. Among 588 participants, 24 developed CVD, yielding 26 events over 3 years (cumulative incidence, 4.1%). Ischemic heart disease was the most frequent event. Exploratory analyses suggested that older age, dyslipidemia, and current smoking were associated with CVD occurrence, although estimates were imprecise because of the limited number of events. Antiplatelet or anticoagulant therapy was administered to selected patients, and hemostatic management was frequently modified following CVD events. One major bleeding event was observed among patients receiving antithrombotic therapy. This prespecified interim analysis provides prospective real-world data on the occurrence and clinical management of CVD in aging Japanese PWH. Risk factor analyses should be considered exploratory, and continued follow-up is required to define long-term cardiovascular risk and outcomes in this population.

Indexed as

Anticoagulant therapyCardiovascular diseasesCardiovascular risk factorsHemophiliaThrombotic disorders

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.